OncLive | Bringing the Global Oncology Community Together

The FDA has approved niraparib (Zejula) for the treatment of patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with ≥3 or more prior chemotherapy regimens, and whose... Read More >>

FDA Recommends Boxed Warning, Additional Labeling Measures for Breast Implants

Apalutamide Preserves HRQoL in Metastatic Castration-Sensitive Prostate Cancer

Immunotherapies, Novel Agents Push Envelope in SCLC

Pivoting Away From the Biomarker Hunt in Gastric Cancer

Novel BISCAY Trial Looks Toward Future of Bladder Cancer Treatment

View More Stories >>

View Conference Coverage

2019 Hairy Cell Leukemia Foundation Annual Conference

2019 Lynn Sage Breast Cancer Symposium

2019 ESMO Congress

17th International Myeloma Workshop

2019 Society of Hematologic Oncology Annual Meeting

Dr. Bekaii-Saab on the Rationale to Explore Tucatinib/Trastuzumab in <em>HER2</em>-Overexpressing mCRC

Dr. Bekaii-Saab on the Rationale to Explore Tucatinib/Trastuzumab in HER2-Overexpressing mCRC

Dr. George on the Changing Treatment Landscape in Prostate Cancer

Dr. Kris on the Impact of Bevacizumab Biosimilars in Lung Cancer

Dr. Perl on Challenges of Implementing Immunotherapy in AML

Dr. Mahoney on Potential of VISTA-Targeting Therapy in RCC

Dr. Siddiqi on Rationale for the TRANSCEND CLL 004 Trial in CLL/SLL

OncLive houses thousands of videos that provide updates and information.
See more Videos

I/O Combination Regimens & the Importance of Biomarkers

First-line Immunotherapy: IMPower133 Regimen

Implications for I/O Therapy in the Treatment of HCC

Liver Pathobiology's Role in Hepatocellular Carcinoma

OncLive houses thousands of videos that provide updates and information.
See more Videos

Envisioning Use of TRK Inhibitors in Clinical Practice

Other Approaches to TRK-Fusion Cancers

Why RET Alteration is an Attractive Target for Therapy

TRK Inhibition in CNS Tumors or Metastases

Treating Pediatric Patients With TRK Inhibitors

Acute GVHD: An Evolving Treatment Paradigm

Treating Acute GVHD With Novel Strategies

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured

ESMO Data Show More Can Be Done for Cancer of Unknown Primary Patients

Two research papers presented by Roche and Foundation Medicine at the 2019 European Society of Medical Oncology Annual Meeting demonstrate both the promise of an innovative precision medicine driven clinical trial (CUPISCO) for patients with cancer of unknown primary, as well as the challenges of identifying eligible patients for the trial.

View more >>>

Featured

TRK Inhibitors: Precision Medicine in Oncology

Benjamin Levy, MD; Mark Agulnik, MD; Marcia Brose, MD, PhD; Edward Kim, MD; John Marshall, MD; and Philip Agop Philip, MD, PhD, FRCP, discuss the use of TRK inhibitors in oncology.

View more >>>

Featured Video

Dr. Esteva on the Future of Biosimilars in Breast Cancer

Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States. View now

FDA Approval in Myeloma, Label Update in HER2+ Breast Cancer, Breakthrough Status in Prostate Cancer, and More